City of Hope (T Cell Manufacturing)

Duarte, CA
National Center
210 confirmed programs · 132 sponsors · Last scored 2026-04-29
83.8
Signal Score
✓ FDA Inspections (3) ✓ Clinical Trials (210) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: City of Hope (T Cell Manufacturing)

Signal Score
83.8/100 (as of 2026-04-29)
Quality Compliance
96.9/100
Headquarters
Duarte, CA
Modalities
CAR-T, Cell Therapy
Active Programs
210 confirmed from ClinicalTrials.gov across 132 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About City of Hope (T Cell Manufacturing)

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 96.9
FDA Inspections3 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-08-20)
Operations 98.9
210 active programs across 132 sponsors
Modalities: Cell Therapy, CAR-T
128 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
210 active programs across 132 sponsors · Modalities: Cell Therapy, CAR-T · 128 programs in advanced phases (Phase 2/3)
Programs 210
Sponsors132
ModalitiesCAR-T, Cell Therapy
210 active programs across 132 sponsors
Modalities: Cell Therapy, CAR-T
128 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT02943642 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion... PHASE2 Withdrawn
NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With... PHASE1 Recruiting
NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment... PHASE3 Recruiting
NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called... PHASE1/PHASE2 Recruiting
NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation... PHASE1 Recruiting
NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients... PHASE1/PHASE2 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting
NCT06859424 A Platform Protocol to Investigate Post-Transplant... PHASE2 Recruiting
View all 210 programs →
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026
Financial Stability 68.0
Parent company: City of Hope
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: City of Hope
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Duarte, CA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

City of Hope (T Cell Manufacturing) FDA Inspection History

2025-08
2025-02
2024-12
NAI VAI OAI
Date Site Type Observations Classification
2025-08-20 Duarte, California Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2025-02-07 Duarte, California Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2024-12-09 Irvine, California Blood and Blood Products No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Jul 04, 2026

City of Hope (T Cell Manufacturing) FDA 483 Findings 3 observations · 2025-08-20 → 2025-08-20 ?

By subsystem

  • Laboratory Controls 2 (66.7%)
  • Documentation & Records 1 (33.3%)

By severity

  • 3 — Moderate: 2
  • 2 — Minor: 1
  • Repeat observations: 0

Most severe findings

  • Moderate (3) Laboratory Controls 2025-08-20 21 CFR 211.194(a)(2)
    Suitability of testing methods verified

    "The suitability of all testing methods is not verified under actual conditions of use."

  • Moderate (3) Laboratory Controls 2025-08-20 21 CFR 211.160(b)
    Scientifically sound laboratory controls

    "Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that components conform to appropriate standards of identity, strength, quality and purity."

  • Minor (2) Documentation & Records 2025-08-20 21 CFR 211.22(d)
    Procedures not in writing, fully followed

    "The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed."

Clinical Activity 210 studies

NCT02943642 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in... PHASE2 Withdrawn NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With Advanced... PHASE1 Recruiting NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus... PHASE3 Recruiting NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404... PHASE1/PHASE2 Recruiting NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in... PHASE1 Recruiting NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration... PHASE1/PHASE2 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based... PHASE2 Recruiting NCT07075185 A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and... PHASE1 Recruiting NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases PHASE1 Enrolling By Invitation NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting NCT06657144 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other... PHASE1 Recruiting NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult... PHASE2 Recruiting NCT06528301 A Phase 1 Study of UB-VV111 With and Without Rapamycin in... PHASE1 Recruiting NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in... PHASE2 Recruiting NCT06699212 A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in... PHASE3 Recruiting NCT06667076 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in... PHASE2 Recruiting
+ 190 more studies
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026

Frequently Asked Questions About City of Hope (T Cell Manufacturing)

How many FDA inspections does City of Hope (T Cell Manufacturing) have on record?
CDMO Signal tracks 3 FDA inspections for City of Hope (T Cell Manufacturing), sourced from the FDA inspection database. See the full inspection history above.
Has City of Hope (T Cell Manufacturing) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for City of Hope (T Cell Manufacturing).
How many clinical programs is City of Hope (T Cell Manufacturing) linked to?
City of Hope (T Cell Manufacturing) is associated with 210 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is City of Hope (T Cell Manufacturing)'s CDMO Signal Score?
City of Hope (T Cell Manufacturing) has a Signal Score of 84/100, based on quality, operations, financial stability, and capacity data.
Evaluating City of Hope (T Cell Manufacturing) for a manufacturing program?
Use the free AI matchmaker to compare City of Hope (T Cell Manufacturing) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Cellares
South San Francisco, CA
Signal Score: 61.5
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody